Skip to content

Study · Systematic review · 2020

2 results

Antidiabetic Drugs in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review.

Muñoz-Jiménez M, Zaarkti A, García-Arnés JA, García-Casares N

Dementia and geriatric cognitive disorders20 Oct 2020Cited by 42 (Europe PMC)

PMID33080602 (opens in a new tab)DOI10.1159/000510677 (opens in a new tab)PepBankPUB-33080602
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a systematic review of trials in patients with Alzheimer's disease, mild cognitive impairment or subjective cognitive complaints, liraglutide showed promising results, with only 2 clinical trials.

    In plain wordsA review of trials in patients with Alzheimer's disease or memory problems found liraglutide results promising, from only 2 trials.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedCognition in Alzheimer's disease or mild cognitive impairment
    Study

    n: not reported in source

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Metformin and liraglutide showed promising results, but further research is needed as just 2 clinical trials involved each of these drugs
    1 context sentence
    Summary · context
    We conducted a search in the electronic databases PubMed/MEDLINE, EMBASE, and Scopus seeking clinical trials evaluating the effect on cognition of antidiabetic drugs in patients with AD, MCI, or SCCs.

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In a systematic review of antidiabetic drugs in Alzheimer's disease and mild cognitive impairment, almost all drugs tested, pooled across drugs, modulated Alzheimer's biomarkers and imaging.

    In plain wordsA review found that almost all the antidiabetic drugs tested, as a group, changed Alzheimer's disease biomarkers and brain imaging.

    Peptide
    Liraglutide
    Outcome
    Not applicableAlzheimer's disease biomarkers and imaging, across antidiabetic drugs
    Study

    n: not reported in source

    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    Almost all drugs tested were shown to modulate AD biomarkers and imaging.
    1 context sentence
    Summary · context
    We conducted a search in the electronic databases PubMed/MEDLINE, EMBASE, and Scopus seeking clinical trials evaluating the effect on cognition of antidiabetic drugs in patients with AD, MCI, or SCCs.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.